OCC 0.00% 37.0¢ orthocell limited

Ann: First Human Tendons Grown in Laboratory, page-21

  1. 2,317 Posts.
    I like this one a lot as a medium to long term investment. I can see it being multiples of its current price next year. I'm not sure about the Achilles tendon study I thought it was completed last year but other literature says it was completed 2nd qtr 2014 and results due this qtr. They have so many trials going on which also have complimentary applications it gets confusing ( for me anyway ).

    The broker report lists these as short tem share price catalysts.
    Q4 CY14: Results of 90 patient study for Ortho-ATI™ to be used for Japanese, European and USA product approval processes.
    Q4 CY14: Results of Phase 1 clinical study for CelGro™
    Q2 CY15: Ortho-ATI™ expected to be added to Australian Register of Therapeutic Goods (ARTG).
    Q3 CY15: 3-5 year clinical data for Ortho-ATI™ expected to be published in a prestigious American Journal.
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
(20min delay)
Last
37.0¢
Change
0.000(0.00%)
Mkt cap ! $77.45M
Open High Low Value Volume
37.0¢ 37.0¢ 37.0¢ $24.88K 67.25K

Buyers (Bids)

No. Vol. Price($)
2 63513 36.5¢
 

Sellers (Offers)

Price($) Vol. No.
37.0¢ 11005 1
View Market Depth
Last trade - 10.28am 24/06/2024 (20 minute delay) ?
OCC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.